Paris, France, September 29, 2022, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate and present at the following upcoming medical conferences before the end of 2022:

 

The American Academy of Ophthalmology (AAO) Annual Meeting

September 30 – October 3, 2022 – Chicago, US

Presentation: The Phase 3 REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)

Type: Oral

Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom, Principal Investigator of REFLECT

Time: Saturday, October 1, 2022 at 09:45 – 09:52 am CDT / 4:45 – 4:52 pm CEST

Location: S405

 

Presentation: Optogenetics in the Clinic: Safety and Efficacy Updates on the Phase ½ Clinical Trial PIONEER

Type: Poster

Presenter: José-Alain Sahel, MD, University of Pittsburgh School of Medicine, US, and Co-Founder of GenSight Biologics

Time: Sunday, October 2, 2022 at 11:45 am – 12:45 pm CDT / 6:45 – 7:45 pm CEST

Location: Poster Theater: Retina, Vitreous

 

Mitochondrial Diseases Conference (Mitocon) 2022

October 7 – 9, 2022 – Rome, Italy

Presentation: Progress in clinical research for new treatment options for LHON: an exciting landscape in front of Patients and Clinicians

Type: Oral

Presenter: Lorena Castillo, MD, Head of the Neuro-Ophthalmology and Teaching Departments at Institut Català Retina, Barcelona, Spain

Time: Saturday, October 8, 2022 at 9:00 – 9:20 am CEST

Location: Plenary Room

 

Presentation: Gene Therapy Development in Leber Hereditary Optic Neuropathy

Type: Oral

Presenter: Magali Taiel, MD, Chief Medical Officer at GenSight Biologics

Time: Saturday, October 8, 2022 at 9:20 – 9:30 am CEST

Location: Plenary Room

 

 23rd European Association for Vision and Eye Research (EVER) Congress

October 13 – 15, 2022 – Valencia, Spain

Presentation: The Phase 3 REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)

Type: Oral

Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, United Kingdom, and Principal Investigator of REFLECT

Time: Saturday, October 15, 2022 at 2:15 – 3:30 pm CEST

Location: RAPID FIRE 2- NSPH – Gaudi 2

Contacts